Patent · US Active

Compositions and methods for inhibiting expression of ADAMTS-5 and ADAM17

US10709729B2 · kind B2 · utility

2Cited by
1References
7Claims
0Family size

Assignees

Inventors

Key dates

Filing dateDec 23, 2015
Grant dateJul 14, 2020
Priority date
Expiry dateDec 23, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/3341
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are siRNAs or chemically-modified siRNAs targeted against ADAMTS-5 or ADAM17 for inhibiting the expression of ADAMTS-5 or ADAM17. Use of the siRNAs for treating an ADAMTS-5 or ADAM17 associated disease, such as arthritis and other inflammation-related diseases, by injecting the siRNAs or preparations comprising the siRNAs into an articular cavity of the patient, are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.